Tag: Genentech
Improving Outcomes in the Treatment of Breast Cancer (Video)
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.
The development of these promising new therapeutic agents...
London Calling: The Cutting-edge of Novel ADC Technologies
Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...
Biparatopic HER2-targeting Antibody-drug Conjugate Demonstrates Potent Antitumor Activity
HER2-targeted therapies have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of breast cancer. Being overexposed in 20-25% of human breast cancers...
Phase I Study Supports Therapeutic Potential of Polatuzumab Vedotin in non-Hodgkin...
Lymphoma - with its main forms Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) - is the most common blood cancer which occurs when cells...
Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...
Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...
ADC Market to Reach US$ 3 Billion by 2018
According to a report published by Research & Markets, one of the world's largest and most respected market research resource, the global market for Antibody-drug...
SAR3419 Achieved Objective Responses Well Above Study Threshold and was Found...
A novel anticancer therapeutic called coltuximab ravtansine (CoR; SAR3419; Sanofi) shows favorable results in the Phase II STARLYTE trial in diffuse large B-cell lymphoma (DLBCL). SAR3419 is a humanized CD19 mAb linked to DM4, a maytansine analog, developed by ImmunoGen.
DEDN6526A Shows Early Promise Against Melanoma
According to results of a first-in-human phase I clinical trial presented at the Annual Meeting of the American Association for Cancer Research (AACR), being...
Study Shows Combination of Epratuzumab and Rituximab in Newly Diagnosed Follicular...
The combination of epratuzumab, a humanized anti CD-22 monoclonal antibody, and rituximab (Rituxan®/Genentech; MabThera®/Roche), as a front-line therapy of patients with newly diagnosed follicular lymphoma (FL), produced...
From the Editors: Welcome to a New Publication – ADC Review/Journal...
Welcome to ADC Review, Journal of Antibody-Drug Conjugates, a new online, peer-reviewed, open-access hybrid publication for those involved in the ongoing--and exciting--development of antibody-drug...
